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Abstract
Background:  The metabolic syndrome appears to affect 10% to 25% of adult population
worldwide. Several studies have described the association between metabolic syndrome and
ischaemic heart disease, however, none linked metabolic syndrome to ischemic mitral
regurgitation, a serious clinical problem facing both the cardiologists and cardiac surgeons. Ischemic
mitral regurgitation is mitral insufficiency caused by myocardial infarction. The myocardial ischemia
can result in altered ventricular geometry, leading to mitral insufficiency. Interestingly metabolic
syndrome showed more pronounced alteration of left ventricular geometry and function especially
in obese subjects.
Presentation of the hypothesis: We have recently proposed that there is link between
metabolic syndrome and ischemic mitral regurgitation and associated complications. Operative
strategy for moderate ischaemic mitral regurgitation continues to be debated between
revascularisation alone and concomitant valve repair at the time of coronary artery bypass surgery.
Each of the above group has published studies, with results supporting each argument.
Testing the hypothesis: Generally speaking the treatments available for metabolic syndrome are
based in both life style modification (dietary advice and advice to increase physical activity) and
medical treatment to enhance insulin sensitivity. Randomised controlled trials may show whether
the current available treatment of metabolic syndrome may have an impact on moderate ischemic
mitral regurgitation.
Implications of the hypothesis: Metabolic syndrome was shown to alter left ventricular
geometry and therefore it is possible to postulate that the variation in the response of different
patients with moderate ischemic mitral regurgitation to current management may be attributed to
the absence and presence of metabolic syndrome. Research testing of this hypothesis in the future
may reveal whether concomitant treatment of metabolic syndrome will play part in the
management of moderate ischemic mitral regurgitation.
Background
The clustering of insulin resistance, dysglycemia, dyslipi-
demia, hypertension and central obesity represent the
major features of metabolic syndrome. These clusters of
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factors may share common etiology and each of which is
a risk factor for cardiovascular disease. The metabolic syn-
drome appears to affect 10% to 25% of adult populations
worldwide. Several studies have described the association
between metabolic syndrome, diabetes and cardiovascu-
lar disease. Definitions of the metabolic syndrome that
also include a measure of central obesity have been devel-
oped between 1999 and 2001 by the World Health
Organization (WHO Consultation, 1999), The European
Group for the Study of Insulin Resistance and the
National Cholesterol Education Program (NCEP).
Recently the International Diabetes Federation produced
worldwide consensus definition of the metabolic syn-
drome in 2005. The criteria for this definition are a waist
circumference of ≥ 94 cm for European men and ≥ 80 cm
for European women (With lower cut-points for some
other ethnic groups) and two or more of the following:
Blood pressure, triglyceride and HDL-cholesterol cut-
points as for the ATP-III definitions and fasting plasma
glucose 5.6 mmol/L [1,2].
Presentation of the hypothesis
A search of the Medline to date has shown that several
studies addressed the link between metabolic syndrome
and ischemic heart disease (IHD). However, none linked
metabolic syndrome to ischemic mitral regurgitation
(IMR), a serious clinical problem facing both the cardiol-
ogists and cardiac surgeons. Ischemic mitral regurgitation
is mitral insufficiency caused by myocardial infarction.
Myocardial infarction always precedes IMR. The leaflets
and subvalvular apparatus are by definition normal. The
disease must be distinguished from mitral regurgitation
(MR) associated with coronary artery disease in which no
cause and effect relationship exists. Mitral regurgitation
associated with dilated cardiomyopathy and profound
left ventricular (LV) dysfunction is a related phenomenon
but should be considered etiologically distinct from IMR.
Ischemic mitral regurgitation is a serious and important
complication that adversely affects the patient's prognosis
in the chronic post-myocardial infarction phase [3]. The
myocardial ischemia can result in altered ventricular
geometry causing the inferioposterior wall to bulge out-
ward, displacing the attached papillary muscles apically
and outward. The leaflets, tethered at both end, cannot
close effectively and are restrained within the left ventri-
cle; this effect is compounded by a decrease in the ven-
tricular force to close the leaflet thus causing IMR. It is
associated with higher cardiovascular mortality within 5
years if left uncorrected [3].
Patients with metabolic syndrome represent a high-risk
group for coronary heart disease as well as for type II dia-
betes. Interestingly metabolic syndrome showed more
pronounced alteration of left ventricular geometry and
function (increased relative wall thickness of LV dimen-
sion and mass, left atrial diameter and decreased mitral E/
A ratio). From multiple regressions analysis metabolic
syndrome was the main independent determinant of LV
mass index [4-6]. Further analysis of the Strong Heart
Study showed that in over-weight and obese adolescents
there was an increase in LV mass, while obesity was asso-
ciated with mildly reduced LV myocardial performance
and increased left atrial force to contribute to LV filling
[6]. We have recently proposed that there is link between
metabolic syndrome and IMR and associated complica-
tions [2].
Importantly, Hickey et al and the SAVE (Survival and Ven-
tricular Enlargement) Study, showed the prevalence of
IMR was around 19 % [7,8]. It is well established that
mitral valve repair or replacement is of significant benefit
in patients with severe IMR, while those with mild IMR
are generally offered coronary artery bypass grafting
(CABG) alone, with acceptable early and late results [4].
However, in cases of moderate ischaemic mitral regurgita-
tion operative strategy continues to be debated between
revascularisation alone and concomitant valve repair.
There are two schools of thoughts regarding the surgical
strategies for the treatment of moderate IMR. The first
school, advocate more liberal use of annuloplasty tech-
niques to repair the mitral valve at the time of revascular-
isation. The rationale for such treatment; firstly it was
reported that CABG alone for moderate IMR leaves many
patients with significant residual MR [9]. Secondly,
Mallidi et al 2004, has shown that patients with uncor-
rected mild to moderate IMR at the time of CABG had a
poorer event-free survival, worse late functional status and
worsening in the degree of mitral regurgitation [10].
Thirdly, Bolling et al has reported that nearly all patients
undergoing mitral valve repair at the time of CABG had
improvement in their angina status [11]. Finally in a ret-
rospective study of 467 patients with moderate IMR who
underwent CABG alone, moderate ischemic mitral regur-
gitation did not reliably resolve with CABG surgery alone
and it was associated with significantly reduced survival
[12].
On the other hand, surgeons who favour CABG alone to
treat moderate IMR present the following arguments.
First: the Emory University research group and other
investigators concluded that excellent hospital survival
and long-term functional stability was achieved with
CABG alone. Secondly, it was reported that patients who
undergo ring annuloplasty for IMR often have persistent
or late recurrence of their MR associated with continued
LV remodeling and this may be difficult to treat [13].
Thirdly, addition of mitral valve procedure at the time of
CABG significantly increases operative mortality andPublish with BioMed Central    and   every 
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reduces long-term survival [14]. Finally, redo surgery car-
ries significant risks.
None of the above studies mentioned whether the pres-
ence of metabolic syndrome may have determinant
impact on patients who are offered CABG or subjected to
surgical correction of moderate IMR. Metabolic syndrome
was shown to alter LV geometry and therefore it is possi-
ble to postulate that the variation in the response of differ-
ent patients with moderate IMR to current management
may be attributed to the absence and presence of meta-
bolic syndrome.
Testing the hypothesis
Generally speaking the treatments available for metabolic
syndrome are based in both life style modification (die-
tary advice and advice to increase physical activity) and
medical treatment to enhance insulin sensitivity. Ran-
domised clinical trial may show whether the current avail-
able treatment of metabolic syndrome may have an
impact on moderate ischemic mitral regurgitation.
Implications of the hypothesis
Research testing of this hypotheses in the future may
reveal whether concomitant treatment of metabolic syn-
drome will also play part in the management of moderate
IMR.
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